Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Regulus HCV Candidate Is Out, But New CEO Has BD Pedigree

Executive Summary

The micro-RNA-focused biotech believes the jaundice seen with HCV candidate RG-101 was specific to the drug, not the target or delivery system, but is switching focus to other promising programs, such RG-012 for Alport syndrome.


Related Content

Finance Watch: Regulus Shrinks To Preserve Cash, Ironwood Cuts Jobs Ahead Of Split
With Dicerna's NASH Asset, Boehringer Found What It Was Looking For
Finance Watch Public Company Edition: Akcea, Kala Launch IPOs While FOPOs Keep Busy Pace
Dicerna, Flush With Cash, Is Back To The Drawing Board
Dicerna, Flush With Cash, Is Back To The Drawing Board
Regulus RNAi Candidate Can Reduce HCV Treatment To Four Weeks
Regulus HCV Candidate On Clinical Hold After Second Jaundice Report
Regulus Rises On HCV Data, But Will Injection Find A Market?
AstraZeneca signs up Regulus in microRNA deal
Sanofi-Aventis signs $750 million microRNA deal with Regulus


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts